Amorphization of a crystalline active pharmaceutical ingredient and thermoanalytical measurements on this glassy form

Journal of Thermal Analysis and Calorimetry

Volumn 102, Issue 1, 2010, Pages 243-247

  Jójárt Laczkovich, Orsolya ^a   Szabó Révész, Piroska ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Amorphization; Clopidogrel hydrogen sulfate; DSC; Ft ir spectroscopy; Solvent method; Tg; X ray powder diffraction

Indexed keywords

CLOPIDOGREL; DSC; FTIR SPECTROSCOPY; SOLVENT METHOD; TG;

DIFFERENTIAL SCANNING CALORIMETRY; DIFFRACTION; DRUG PRODUCTS; DRUG PRODUCTS PLANTS; GLASS; GLASS TRANSITION; HYDROGEN; SOLVENTS; X RAY POWDER DIFFRACTION; X RAYS;

AMORPHIZATION;

EID: 78649735349     PISSN: 13886150     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10973-009-0530-5     Document Type: Article

References (28)

1. Cui Y. A material science perspective of pharmaceutical solids. Int J Pharm. 2007; 339: 3-18. (Pubitemid 46977612)
2. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliver Rev. 2001; 48: 27-42. (Pubitemid 32454482)
3. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003; 20: 305-17.
4. Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliver Rev. 2001; 48: 3-26.
5. Rodriguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodriguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv Drug Deliver Rev. 2004; 56: 241-74. (Pubitemid 38201425)
6. Zhang GGZ, Law D, Schmitt EA, Qiu Y. Phase transformation consideration during process development and manufacture of solid oral dosage forms. Adv Drug Deliver Rev. 2004; 56: 371-90. (Pubitemid 38202329)
7. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm. 2005; 293: 155-64. (Pubitemid 40381089)
8. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000; 17: 397-403.
9. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliver Rev. 2004; 56: 335-47. (Pubitemid 38201429)
10. Chadha R, Kashid N, Jain DVS. Characterization and quantification of amorphous content in some selected parenteral cephalosporins by calorimetric method. J Therm Anal Calorim. 2005; 81: 277-84. (Pubitemid 41164952)
11. Craig DQM, Royall PG, Kett VL, Hopton ML. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999; 179: 179-207.
12. g drug. Powder Technol. 2006;167: 20-5.
13. Watanabe T, Hasegawa S, Wakiyama N, Kusai A, Senna M. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int J Pharm. 2003; 250: 283-6. (Pubitemid 35447957)
14. Kim J-H, Choi H-K. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int J Pharm. 2002; 236: 81-5.
15. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method. Powder Technol. 2004; 141: 187-95. (Pubitemid 38726136)
16. Szabó-Révész P, Laczkovich O, Ambrus R, Szüts A, Aigner Z. Protocols for amorphization of crystalline solids through the application of pharmaceutical technological processes. Eur J Pharm Sci. 2007; 32: 26. doi:10.10166j.ejps.2007.05.036.
17. Giron D. Applications of thermal analysis and coupled techniques in pharmaceutical industry. J Therm Anal Calorim. 2002; 68: 335-57. (Pubitemid 34614439)
18. Gombás A, Szabó-Révész P, Kata M, Regdon G Jr, Erös I. Quantitative determination of α-lactose monohydrate by DSC. J Therm Anal Calorim. 2002; 68 :503-10.
19. Kerč J, Srčič S. Thermal analysis of glassy pharmaceuticals. Thermochim Acta. 1995; 248: 81-95.
20. Hancock BC, Zografi G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J Pharm Sci. 1997; 86: 1-12.
21. Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing Clopidogrel: 18 copies versus the original brand. J Pharmaceut Biomed. 2004; 34: 341-8. (Pubitemid 38167764)
22. Bousquet A, Castro B, Germain JS. Polymorphic form of clopidogrel hydrogen sulfate, US Patent 6, 504, 030, Jan 07 2003;
23. ref. Chem. Abstract 132 (2000) 54841n.
24. Uvarov V, Popov I. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixture of clopidogrel bisulphate polymorphs. J Pharmaceut Biomed. 2008; 46: 676-82.
25. Lohray BB, Lohray VB, Pandey B, Dave MG. Polymorph and amorphous form of (S)-(+)-clopidogrel bisulfate, WO 2004/ 081016, 23 Sept 2004.,
26. Németh Z, Demeter A, Pokol Gy. Quantifying low levels of polymorphic impurity in clopidogrel bisulphate by vibrational spectroscopy and chemometrics. J Pharmaceut Biomed. 2009; 49: 32-41.
27. Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening-a review. Eur J Pharm Biopharm. 2009; 71: 23-37.
28. International conference on harmonization Q3C, impurities: residual solvents. 1998. http://www.emea.europa.eu/pdfs/human/ich/028395en.pdf of subordinate document. Accessed March 1998.